Key result
Generalized anxiety disorder is linked to ~2.3-fold higher odds of new-onset hypertension at 12 months.
Why the study?
Generalized anxiety disorder (GAD) may be associated with an increased risk of future hypertension through psychophysiological stress pathways, though this association requires careful evaluation accounting for medication use, lifestyle factors, and baseline biomarkers.
Does generalized anxiety disorder increase the 12-month risk of sustained new-onset hypertension in normotensive outpatients?
Cohort (n=300)
No
Does generalized anxiety disorder increase the 12-month risk of sustained new-onset hypertension in normotensive outpatients?
Generalized anxiety disorder is independently associated with a more than two-fold higher odds of developing new-onset hypertension at 12 months, partially mediated by elevated cortisol and impaired heart rate variability.
Answers are grounded in this paper and cite their sources.
GAD may warrant closer BP monitoring in outpatients; leaves open whether anxiety treatment prevents incident hypertension.
BACKGROUND Generalized anxiety disorder (GAD) may be associated with an increased risk of future hypertension through psychophysiological stress pathways; however, this association must be interpreted carefully, considering medication use, lifestyle factors, clinic-based selection, and limited temporal information provided by baseline biomarkers. AIM To explore the potential impact of GAD on future hypertension risk and preliminarily analyze the roles of psychophysiological stress-related pathways (neuroendocrine, sympathetic activation, and inflammatory response) in the same. METHODS This was a prospective, observational cohort study. A total of 300 outpatients and physical examination participants from January 2023 to December 2024 at Southern Medical University Shenzhen Hospital were included; no participants had hypertension at baseline. The participants were divided into a GAD group (n = 96) and a non-GAD group (n = 204) according to the DSM-5 diagnosis and the GAD-7 scale. Data on general information, lifestyle factors, dietary salt intake, physical activity, family history, psychotropic/hypnotic medication use, and sleep quality were collected. Early morning serum cortisol, C-reactive protein, interleukin-6, 24-hour ambulatory blood pressure, and heart rate variability parameters were obtained. All participants were followed up for 12 months and sustained new-onset hypertension was recorded. Multivariate and sensitivity analyses were performed to assess the association between GAD and hypertension, while mediation analysis was used as exploratory statistical decomposition rather than causal pathway confirmation. RESULTS All 300 participants completed the 12-month follow-up; 50 cases of new-onset hypertension were observed. Incident hypertension occurred in 36/96 (37.5%) participants in the GAD group, significantly higher than 14/204 (6.9%) in the non-GAD group. After adjusting for demographic factors, body mass index, smoking and alcohol use, sleep quality, baseline blood pressure, family history of hypertension, psychotropic/hypnotic medication use, physical activity, and dietary salt intake, GAD remained associated with a higher risk of new-onset hypertension in the expanded penalized model (adjusted odds ratio = 2.31, 95% confidence interval: 1.23-4.38). Replacing the dichotomous GAD status with a continuous GAD-7 score yielded a consistent association. Compared to the non-GAD group, the GAD group showed higher levels of cortisol, C-reactive protein, and interleukin-6, and heart rate variability (HRV) indices indicated impaired sympathovagal balance. Exploratory mediation analysis suggested that increased cortisol levels and a standardized HRV composite jointly explained 32.5% of the association between GAD and incident hypertension, while inflammatory markers showed borderline or positive indirect-effect trends. CONCLUSION GAD was associated with a higher 12-month risk of sustained new-onset hypertension in this clinic-based cohort; this association persisted after adjustment for common clinical, medication-related, and lifestyle confounders. Elevated cortisol levels and reduced HRV may statistically explain part of this association; however, mediation findings should not be interpreted as definitive causal pathways. Clinically, dynamic blood pressure monitoring, anxiety assessment, medication review, sleep management, and lifestyle interventions should be considered in patients with GAD.
No takes yet. Share an insight, caveat, or question.
Ouyang et al. (2026) conducted a cohort in Generalized anxiety disorder without baseline hypertension (n=300). Generalized anxiety disorder (GAD) according to DSM-5 diagnosis and GAD-7 scale vs. Non-GAD group (no generalized anxiety disorder) was evaluated on Sustained new-onset hypertension at 12 months (OR 2.31, 95% CI 1.23-4.38). Generalized anxiety disorder was associated with a higher 12-month risk of new-onset hypertension vs no GAD.
Synapse has enriched 10 related papers. Consider them for comparative context: